Filing excerpt
In June 2026, the Company received a letter from Pfizer inquiring about the Company’s plan for payment to Pfizer under the foregoing agreement. The Company disagrees that the payment Pfizer requests is owed. Any loss to the Company as a result of the foregoing disagreement could have an adverse impact on Viatris.